Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations.
Ursula GraziniAleksandra A MarkovetsLucy IrelandDaniel O'NeillBenjamin PhillipsMan XuMatthias PfeiferTereza VaclovaMatthew J MartinLudovic BigotLuc FribouletRyan J HartmaierMaria Emanuela CuomoSimon T BarryPaul D SmithNicolas Floc'hPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Together, this approach offers a potential treatment strategy for patients with EGFRm-driven NSCLC that have a sub-optimal response, or develop resistance, to osimertinib through PIK3CA/AKT/PTEN alterations.